CL2019003421A1 - Nuevos péptidos (seq id n°236), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) - Google Patents

Nuevos péptidos (seq id n°236), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)

Info

Publication number
CL2019003421A1
CL2019003421A1 CL2019003421A CL2019003421A CL2019003421A1 CL 2019003421 A1 CL2019003421 A1 CL 2019003421A1 CL 2019003421 A CL2019003421 A CL 2019003421A CL 2019003421 A CL2019003421 A CL 2019003421A CL 2019003421 A1 CL2019003421 A1 CL 2019003421A1
Authority
CL
Chile
Prior art keywords
peptides
cancer
seq
carriers
combinations
Prior art date
Application number
CL2019003421A
Other languages
English (en)
Inventor
Andrea Mahr
Toni Weinschenk
Oliver Schoor
Jens Fritsche
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1515321.6A external-priority patent/GB201515321D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2019003421A1 publication Critical patent/CL2019003421A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A PÉPTIDOS (SEO ID NO; 236), PROTEÍNAS, ÁCIDOS NUCLEICOS Y CÉLULAS DESTINADOS A LA UTILIZACIÓN EN MÉTODOS INMUNOTERAPÉUTICOS. EN PARTICULAR, LA PRESENTE INVENCIÓN SE REFIERE A LA INMUNOTERAPIA CONTRA EL CÁNCER. LA PRESENTE INVENCIÓN SE REFIERE ASIMISMO A EPÍTOPOS PEPTÍDICOS PARA LINFOCITOS T ASOCIADOS A TUMORES, SOLOS O EN COMBINACIÓN CON OTROS PÉPTIDOS ASOCIADOS A TUMORES QUE, POR EJEMPLO, PUEDEN SERVIR COMO PRINCIPIOS ACTIVOS FARMACÉUTICOS EN COMPOSICIONES VACÚNALES DESTINADAS A ESTIMULAR RESPUESTAS INMUNITARIAS ANTITUMORALES, O A ESTIMULAR EX VIVO LINFOCITOS T QUE DESPUÉS SERÁN TRANSFERIDOS A LOS PACIENTES. LOS PÉPTIDOS UNIDOS A MOLÉCULAS DEL COMPLEJO MAYOR DE HISTOCOMPATIBILIDAD (MHC), O LOS PÉPTIDOS COMO TALES, TAMBIÉN PUEDEN SER DIANAS DE ANTICUERPOS, DE RECEPTORES DE LINFOCITOS T SOLUBLES, Y DE OTRAS MOLÉCULAS DE UNIÓN.
CL2019003421A 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°236), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) CL2019003421A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562211276P 2015-08-28 2015-08-28
GBGB1515321.6A GB201515321D0 (en) 2015-08-28 2015-08-28 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Publications (1)

Publication Number Publication Date
CL2019003421A1 true CL2019003421A1 (es) 2020-05-08

Family

ID=62596848

Family Applications (11)

Application Number Title Priority Date Filing Date
CL2018000545A CL2018000545A1 (es) 2015-08-28 2018-02-28 Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer.
CL2018002113A CL2018002113A1 (es) 2015-08-28 2018-08-06 Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipo de cancer (divisonal solicitud 201800545)
CL2019003425A CL2019003425A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°42), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003428A CL2019003428A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°145), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003422A CL2019003422A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°171), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003427A CL2019003427A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°180), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003426A CL2019003426A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003421A CL2019003421A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°236), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003423A CL2019003423A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°378), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003429A CL2019003429A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°70), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003424A CL2019003424A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°244), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)

Family Applications Before (7)

Application Number Title Priority Date Filing Date
CL2018000545A CL2018000545A1 (es) 2015-08-28 2018-02-28 Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer.
CL2018002113A CL2018002113A1 (es) 2015-08-28 2018-08-06 Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipo de cancer (divisonal solicitud 201800545)
CL2019003425A CL2019003425A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°42), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003428A CL2019003428A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°145), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003422A CL2019003422A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°171), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003427A CL2019003427A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°180), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003426A CL2019003426A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2019003423A CL2019003423A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°378), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003429A CL2019003429A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°70), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2019003424A CL2019003424A1 (es) 2015-08-28 2019-11-25 Nuevos péptidos (seq id n°244), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)

Country Status (13)

Country Link
US (14) US11793866B2 (es)
JP (1) JP6742370B2 (es)
CN (2) CN109734777B (es)
AU (1) AU2022268324B2 (es)
CA (1) CA3223546A1 (es)
CL (11) CL2018000545A1 (es)
CO (1) CO2018002902A2 (es)
IL (3) IL309003A (es)
MX (2) MX2022001319A (es)
PH (1) PH12018500395A1 (es)
TW (5) TWI794761B (es)
UA (1) UA125817C2 (es)
ZA (2) ZA201801085B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108250286B (zh) * 2016-12-28 2021-06-08 香雪生命科学技术（广东）有限公司 源自于pasd1的肿瘤抗原短肽
CN110907647B (zh) * 2019-10-29 2022-08-30 南通大学附属医院 Clec5a基因的新用途
CN114107345A (zh) * 2021-11-22 2022-03-01 北京大学人民医院 子宫内膜样腺癌相关融合基因检测及其临床应用
CN115785277B (zh) * 2022-09-09 2023-06-20 上海百英生物科技股份有限公司 一种抗IL4i1纳米抗体的制备及其应用
CN117194771A (zh) * 2023-08-01 2023-12-08 广东工业大学 一种图模型表征学习的动态知识图谱服务推荐方法
CN117195280A (zh) * 2023-08-10 2023-12-08 甘肃省水利厅信息中心 一种基于区块链的生态流量监测数据共享系统、服务器及存储介质

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294459B1 (en) 1997-10-15 2007-11-13 President And Fellows Of Harvard College Cell regulatory genes, encoded products, and uses related thereto
EP1064022A4 (en) 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PEPTIDES AND THEIR APPLICATIONS
JP4315301B2 (ja) 1998-10-30 2009-08-19 独立行政法人科学技術振興機構 ヒトＨ３７タンパク質と、このタンパク質をコードする ｃＤＮＡ
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6953672B2 (en) 2001-08-21 2005-10-11 Millennium Pharmaceuticals, Inc. Screen for CDC7 inhibitors
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
WO2004099243A2 (en) 2003-05-05 2004-11-18 Pharmacia Italia S.P.A. Truncated forms of human dbf4, complexes with their interacting partners and methods for identification of inhibitors thereof
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
JP4721903B2 (ja) 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
DK1760088T3 (da) 2005-09-05 2008-06-09 Immatics Biotechnologies Gmbh Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler
HUE027057T2 (en) 2007-07-27 2016-08-29 Immatics Biotechnologies Gmbh New immunogenic epitope for immunotherapy
US20110111711A1 (en) 2008-03-31 2011-05-12 Agency For Science, Technology And Research High Efficiency Linear Transmitter
TW201000115A (en) 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2756298A4 (en) 2011-09-12 2015-08-12 Creatics Llc NON-INVASIVE METHODS OF DETECTING TARGET MOLECULES
EP2788012A4 (en) 2011-11-11 2015-08-05 Cedars Sinai Medical Center COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
CA2880331A1 (en) * 2012-08-15 2014-02-20 Universite De Montreal Method for identifying novel minor histocompatibility antigens
JP6445467B2 (ja) 2013-02-28 2019-01-09 バイオケア メディカル， エルエルシー 抗ｐ４０抗体システムおよび方法
WO2014160275A2 (en) 2013-03-14 2014-10-02 Battell Memorial Institute Biomarkers for liver fibrosis
TWI777195B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（三）
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction

Also Published As

Publication number Publication date
US20230181707A1 (en) 2023-06-15
TW202140515A (zh) 2021-11-01
IL309003A (en) 2024-01-01
US11793866B2 (en) 2023-10-24
IL257577A (en) 2018-04-30
CL2019003429A1 (es) 2020-05-15
TWI782433B (zh) 2022-11-01
US11975058B2 (en) 2024-05-07
US11951160B2 (en) 2024-04-09
US11547750B2 (en) 2023-01-10
TWI782434B (zh) 2022-11-01
CL2019003423A1 (es) 2020-05-08
US11957742B2 (en) 2024-04-16
AU2022268324B2 (en) 2024-02-29
CA3223546A1 (en) 2017-03-09
TWI794761B (zh) 2023-03-01
AU2022268324A1 (en) 2022-12-15
US20220387566A1 (en) 2022-12-08
US20220249630A1 (en) 2022-08-11
MX2018011388A (es) 2023-04-17
US20220331413A1 (en) 2022-10-20
CN109734777B (zh) 2023-04-07
US20220249632A1 (en) 2022-08-11
CL2018000545A1 (es) 2018-06-01
TW202140068A (zh) 2021-11-01
ZA201801085B (en) 2019-08-28
TW202140514A (zh) 2021-11-01
US20220249633A1 (en) 2022-08-11
US20230226161A1 (en) 2023-07-20
CL2019003424A1 (es) 2020-05-08
PH12018500395A1 (en) 2018-09-03
CL2018002113A1 (es) 2018-09-14
JP2018183174A (ja) 2018-11-22
US20220160851A1 (en) 2022-05-26
CL2019003422A1 (es) 2020-05-08
IL292864A (en) 2022-07-01
US11541107B2 (en) 2023-01-03
CO2018002902A2 (es) 2018-06-20
US11744882B2 (en) 2023-09-05
US20220226452A1 (en) 2022-07-21
MX2022001319A (es) 2022-05-03
CN109734777A (zh) 2019-05-10
CL2019003428A1 (es) 2020-05-15
TW202140529A (zh) 2021-11-01
US20220233664A1 (en) 2022-07-28
CN115925806A (zh) 2023-04-07
US20220233663A1 (en) 2022-07-28
TWI803835B (zh) 2023-06-01
CL2019003427A1 (es) 2020-05-15
CL2019003426A1 (es) 2020-05-15
UA125817C2 (uk) 2022-06-15
CL2019003425A1 (es) 2020-05-15
ZA201806844B (en) 2020-02-26
JP6742370B2 (ja) 2020-08-19
US20220323560A1 (en) 2022-10-13
US20220175898A1 (en) 2022-06-09
TWI796642B (zh) 2023-03-21
TW202140516A (zh) 2021-11-01
US11576954B2 (en) 2023-02-14
US20220226451A1 (en) 2022-07-21
US11559572B2 (en) 2023-01-24

Similar Documents

Publication Publication Date Title
CL2019003311A1 (es) Nuevos péptidos (seq id no:82) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
CL2019003421A1 (es) Nuevos péptidos (seq id n°236), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2020000983A1 (es) Nuevo péptido de seq id no: 34 para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer (divisional de la solicitud no. 201701819)
CL2020001897A1 (es) Tratamientos contra el cáncer de útero. (divisional solicitud 201802508)
CL2020000817A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer (divisional solicitud 201902093)
CL2019002880A1 (es) Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer.
CL2018000780A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer
CR20180245A (es) Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer
CL2018002610A1 (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer
CL2020000020A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres.
CL2019002878A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer.
CL2018001533A1 (es) Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer
CL2017002407A1 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
CL2019000460A1 (es) Nuevos péptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cáncer.
CL2020001565A1 (es) Péptidos (seq id no. 119, seq id no. 2 a seq id no. 63, seq id no. 65 a seq id no. 118, y seq id no. 120 a seq id no. 149), combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer. (divisional solicitud 201802360)
CL2019003327A1 (es) Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer. (divisional solicitud 201703244)
CL2017002346A1 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CL2020002856A1 (es) Nuevos péptidos (seq id no: 120) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cáncer (divisional de la solicitud no. 201802096)
CL2020002173A1 (es) Nuevo péptido seleccionado de las seq id no: 3 y 4, y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cáncer. (divisional solicitud 201802827)
AR122218A2 (es) Péptidos y soportes útiles en el tratamiento inmunoterapéutico de varios tipos de cáncer